PO.IM01.10 · 免疫学
Combination Immunotherapies
- 1547 1547 IDH1-R132H通过促进病毒进入和免疫激活增强溶瘤HSV-1对胶质瘤的治疗 IDH1-R132H enhances oncolytic HSV-1 therapy by facilitating viral entry and immune activation in glioma Eleni Panagioti, Hunter J. Kelley, Alexander L. Ling, William Goins, Daniel Roberts, Sotiris Sotiriou, Bryan J. Iorgulescu, Karen Dixon, Michael B. Yaffe, Maria G. Castro, Sean E. Lawler, Gordon J. Freeman, Vijay K. Kuchroo, E Antonio Chiocca, Charles H. Cook
- 1548 1548 T细胞急性淋巴细胞白血病(T-ALL)驱动强大的T细胞应答,可通过aCD40和aPD1联合疗法加以利用 T-cell acute lymphoblastic leukemia (T-ALL) drives robust T cell responses that can be harnessed with aCD40 and aPD1 combination therapy Faizah Alabi, Alex Somma, Todd Triplett
-
1549 · PDF BH3120(一种靶向PD-L1和4-1BB的临床阶段双特异性抗体)与CD3 T细胞衔接器联合应用的非临床特性 Non-clinical characteristics of BH3120, a clinical stage bispecific antibody targeting PD-L1 and 4-1BB, in combination with CD3 T cell engagers Jing Wang, Jun Wang, Yang Liu, Aibo Sun, Aihong Zhang, Haixia Zhao, Renai Guo, Jie Feng, Jiangcheng Xu, Jiawang Liu, Kyoungwoo Lee
-
1551 · PDF 瘤内可生物降解纳米流控平台用于局部多模式免疫治疗,可增强肿瘤根除并提升免疫记忆 Intratumoral biodegradable nanofluidic platform for localized multimodal immunotherapy enhances tumor eradication and immune memory Jingyi Wang, Francesco Manfredi, Eleonora Molinari, Madison A. Deeson, Danilo Settis, Casey Lewis, Junjun Zheng, Junhua Mai, Shu-Hsia Chen, Corrine Ying Xuan Chua, Alessandro Grattoni
-
1552 · PDF 表观遗传诱导的免疫活化位点染色质可及性增加与抗PD-1治疗的应答相关 Epigenetic induced increased chromatin accessibility of immune activation loci is associated with response to anti-PD-1 therapy Otega Oviri, Tyler Gross, Md Imran Khan, Sean Henry Colligan, Jonathan E. Bard, Roberto Pili
-
1553 · PDF PD-1阻断与DLL3靶向T细胞衔接器联合可增强小细胞肺癌的抗肿瘤疗效 Combining PD-1 blockade with DLL3-targeted T cell engager potentiates antitumor efficacy in small cell lung cancer Tongxin Huo, Ting Ni, Jingjing Wang, Panpan Wang, Yuhe Han, Yawen Zhang, Jian Xiang, Zhixiang Zhang
-
1554 · PDF 将优化的irinotecan制剂与自扩增RNA联合用于治疗免疫抑制性肺转移黑色素瘤模型 Combining an optimized irinotecan formulation with self-amplyfing RNA to treat an immunosuppressive lung metastasis melanoma model XuXin Sun, Nasim Sarrami, Irafasha C. Casmil, Sijie Zhang, Marcel B. Bally, Anna K. Blakney
-
1555 · PDF 患者来源肿瘤球体中肿瘤和免疫对抗PD-1及DGK抑制的差异性应答揭示相加性杀伤效应 Differential tumor and immune responses to anti PD-1 and DGK inhibition in patient-derived tumor spheroids reveal additive killing effect Bihui Melidosian, Julia Vail, Xiaodi Ren, Danielle Hagee, Michael A. Perricone, Cynthia Timmers
-
1556 · PDF 由单克隆抗体包被的靶细胞活化的NK细胞可增强双特异性抗体诱导的T细胞增殖、活化和细胞毒性 NK cells activated by monoclonal antibody-coated target cells enhance bispecific antibody-induced T cell proliferation, activation and cytotoxicity Reza Amani, Jyoti Arora, George J. Weiner
-
1557 · PDF PHST001与标准治疗化疗联合可增强巨噬细胞介导的肿瘤细胞清除 PHST001 combination with standard-of-care chemotherapy enhances macrophage-mediated elimination of tumor cells Giovanni C. Forcina, Kelsey E. Hart, Joseane Sampaio, Joshua D. Rudolph, Suzana A. Kahn, Raphaël F. Rousseau, Amira A. Barkal, Ravindra Majeti, Irving L. Weissman, Roy L. Maute, Jennifer Yinuo Cao
-
1558 · PDF Ziftomenib与CAR T细胞免疫疗法在KMT2A重排(R)急性白血病中的临床前活性 Preclinical activity of ziftomenib and CAR T cell immunotherapy in KMT2A -rearranged (R) acute leukemias Sarah E. Haines, Shubhmita Bhatnagar, Michael C. Yarnell, Samantha M. McClellan, Catherine D. Falkenstein, Linda Kessler, Francis J. Burrows, Lisa M. Niswander, Terry J. Fry, Sarah K. Tasian
-
1559 · PDF 首创的靶向Zalpha结构域的ADAR1 p150抑制剂在高IFN同基因黑色素瘤中展现出强效的抗肿瘤疗效 First-in-class Zalpha-domain-targeted ADAR1 p150 inhibitor demonstrates potent antitumor efficacy in high IFN syngeneic melanoma Aditya Kulkarni, Avijit Goswami, Sandeep Goyal, Princy Khurana, Kawaljit Singh, Barnali Deb
-
1560 · PDF 靶向非经典免疫检查点MUC1-C增强实体瘤中的抗PD-1疗法 Targeting the non-canonical immune checkpoint MUC1-C enhances anti-PD-1 therapy in solid tumors Dae Young Kim, Hee Young Kang, Young Ha Yoon, Sung Min Kim, Hoil Choi
-
1561 · PDF 克服胰腺癌中的免疫抑制:多胺阻断与抗PD-1联合疗法的疗效 Overcoming immunosuppression in pancreatic cancer: Efficacy of polyamine blockade and anti-PD-1 combinational therapy Joseph A. Goode, Diana Estefania Gaete-Alvarez, Savannah Harris, Otto Phanstiel, Deborah A. Altomare
-
1562 · PDF 重塑免疫排斥型肿瘤微环境:Vactosertib/抗PD-1/VEGF抑制剂三联疗法在CRC中重建抗肿瘤免疫 Rewiring the immune-excluded tumor microenvironment: Vactosertib/anti-PD-1/VEGF inhibitor triplet therapy reinstates antitumor immunity in CRC Seong-Jin Kim, Dong Woo Kang, Hye Jin Kim, Seonho Yoo, Jin Beom Bae, June Myoung Kim, Min Kyu Kim, Jinhwan Kim, Jin Su Kim, Ye Seon Kim, Jeong Su Lee, Kwiyeom Yoon
-
1563 · PDF 瘤内IL-12联合HDAC抑制克服检查点难治性肿瘤 Intratumoral IL-12 in combination with HDAC inhibition overcomes checkpoint-refractory tumors Asma S. Khelifa, Ainara Meler, Christine M. Minnar, Katherine E. Lothstein, Masaya Miyamoto, Nicholas Roller, Lisa K. Poppe, David Peeney, Sailaja Battula, Howard L. Kaufman, Jeffrey Schlom, Sofia R. Gameiro
-
1564 · PDF 硼替佐米通过固有免疫激活增强PD-1阻断在肺鳞状细胞癌中的抗肿瘤疗效 Bortezomib enhances anti-tumor efficacy of PD-1 blockade in lung squamous cell carcinoma via innate immune activation Xin Jin, Jianguo Zhong, SIbo Peng, Song Xu
- 1565 1565 在GBM小鼠模型中分析肿瘤治疗电场(TTFields)疗法与检查点抑制剂的同期联用 Analyzing Tumor Treating Fields (TTFields) therapy concomitantly with checkpoint inhibitors in a GBM mouse model Si Yeon Lee, Kwang Bog Cho, Caren Wu, Justin Liu, Joe Ha, Adam Sjoholm, Michael Lim, Gordon Li, Ryan Nitta
-
1566 · PDF 从遗传学和药理学层面靶向宿主ATF4可使胰腺导管腺癌对CAR T细胞疗法和免疫检查点阻断敏感 Genetic and pharmacologic targeting of host ATF4 sensitizes pancreatic ductal adenocarcinoma to CAR T and immune checkpoint blockade Nektarios Kostopoulos, Rohan Ganesh, Tej Patel, Frank Chinga, Dan Boehmler, Arjun Sengupta, Aalim Weljie, Costa Koumeis
-
1567 · PDF 采用SBRT/IL-12疗法对胰腺癌中耗竭T细胞进行重编程 Reprogramming of exhausted T cells in pancreatic cancer with SBRT/IL-12 therapy Sarah Eckl, Gary Hannon, Angela Hughson, Scott A. Gerber
-
1568 · PDF 免疫检查点抑制剂与靶向治疗在原位RCC小鼠模型中的协同抗肿瘤效应 Synergistic antitumor effects of immune checkpoint inhibitors and targeted therapy in an orthotopic RCC mouse model Balaji Ramachandran, Satheeshkumar Rajendiran, Abhilash Reddy, Girish Joshi, Krishnappa Haladasappa
-
1569 · PDF 采用装载ICP34.5的G47Δ溶瘤单纯疱疹病毒治疗PAX3-FOXO1腺泡状横纹肌肉瘤,与抗PD1抗体联合给药时可带来生存获益 Treatment of PAX3-FOXO1 alveolar rhabdomyosarcoma with ICP34.5-armed G47∆ oncolytic herpes simplex virus confers survival benefit when co-administered with anti-Pd1 antibody Cole W. D. Peters, Miriam Valenzuela-Cardenas, Moe Kawakami, Andrew Dinh, Jaden Nguyen, Allison Flores, Theodore S. Nowicki
-
1570 · PDF EGFR与检查点抑制剂联合疗法在自发性结肠癌模型中的临床前评估 Preclinical assessment of EGFR and checkpoint inhibitor combination therapy in spontaneous colon cancer model Balaji Ramachandran, Satheeshkumar Rajendiran, Girish Joshi, Krishnappa Haladasappa
-
1571 · PDF 通过选择性抑制NOX1、2和4可克服CAF介导的癌症免疫治疗耐药 CAF-mediated cancer immunotherapy resistance can be overcome via selective inhibition of NOX1, 2 and 4 Jihyun Um, Heesu Kim, Hye Ji Jang, Eun Sil Lee, Yeonhee Ahn, Sung Hwan Moon, Soo Jin Lee
-
1572 · PDF 鸡尾酒免疫疗法:植物病毒免疫调节剂、HER2抗体及共递送IL-12细胞因子用于治疗HER2+癌症 Cocktail immunotherapy: Plant virus immunomodulator, HER2 antibody, and co-delivered IL-12 cytokine for the treatment of HER2+ cancer Ayumi E. Pottenger, Miguel A. Moreno Gonzalez, Manuel L. Penichet, Nicole F. Steinmetz
-
1575 · PDF 胰腺导管腺癌中PIKfyve与KRAS双重抑制的免疫学意义 Immune implications of dual PIKfyve and KRAS inhibition in pancreatic ductal adenocarcinoma Jasmine P. Wisniewski, Caleb Cheng, Rüya Pakkan, Sydney Peters, Gabriel Cruz, Yuanyuan Qiao, Costas A. Lyssiotis, Arul M. Chinnaiyan
-
1576 · PDF MerTKi与免疫调节性化疗联合治疗可促使三阴性乳腺癌中CXCL9阳性巨噬细胞重编程及抗肿瘤适应性记忆的形成 Combination treatment of mertki and immunomodulatory chemotherapy results in cxcl9 positive macrophage reprogramming and anti tumor adaptive memory in triple negative breast cancer Alex J. Smith, Zachary Schrank, Nan Guan, Diego Pedroza, Sebastian Calderon, Xueying Yuan, Na Zhao, Zoe Gabriel, Yang Gao, Charlotte Rivas, Fengshuo Liu, Chuck Perou, Shelton Earp, Jeffrey M. Rosen